ABOUT CHIME BIOLOGICS
Chime Biologics, is a world-class experienced Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide a comprehensive solution supporting our customers from analytical and process transfer to early-stage biopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for Global Supply.
For more information on Chime Biologics, please visit www.chimebiologics.com.
CHIME BIOLOGICS CONTACTS
Business Contact
bd@chimebiologics.com
Chime Biologics, is a world-class experienced Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide a comprehensive solution supporting our customers from analytical and process transfer to early-stage biopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for Global Supply.
For more information on Chime Biologics, please visit www.chimebiologics.com.
CHIME BIOLOGICS CONTACTS
Business Contact
bd@chimebiologics.com
Location: China, Hubei, Wuhan
Employees: 201-500
Total raised: $190M
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | Biomark Ca... | biomarkcap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.03.2021 | Series A | $190M | - |
Mentions in press and media 13
| Date | Title | Description |
| 12.11.2024 | Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing | Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. Chime Biologics will leverage its CMC expertise in biologics to manage Ant... |
| 09.10.2024 | Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics | SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial inte... |
| 07.03.2024 | Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry | WUHAN, China, March 7, 2024 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management sys... |
| 26.10.2023 | Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia | Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115. The first-in-class mAb will benefit endometriosis and and... |
| 25.09.2023 | Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch | Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will ... |
| 22.09.2023 | Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development | Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203,... |
| 30.06.2023 | Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally | Leads Biolabs and Chime Biologics initiate strategic cooperation to accelerate IND application and provide clinical trial materials in China. BeiGene and Chime Biologics establish strategic cooperation to facilitate IND applications oversea... |
| 27.03.2021 | China’s Chime Biologics nets $190m funding led by VMS Group | Premium Chime Biologics (Wuhan) Co., Ltd, contract development and manufacturing organisation, has completed over $190 million in its Series A+ round of financing led by Hong Kong’s alternative asset management player VMS Group. Continue re... |
| 27.03.2021 | China’s Chime Biologics nets $190m funding led by VMS Group | Chime Biologics (Wuhan) Co., Ltd, contract development and manufacturing organisation, has completed over $190 million in its Series A+ round of financing led by Hong Kong’s alternative asset management player VMS Group. Fidelity Internatio... |
| 26.03.2021 | Chime Biologics Announced the Completion of $190 Million Series A+ Financing to Accelerate Capacity Expansion | March 26, 2021, Wuhan - Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of $190 million Series A+ investment from institutional investors in which over $100 million investment... |
Show more